APA (7th ed.) Citation

Blauvelt, A., Shi, N., Somani, N., Burge, R., Zhu, B., Ridenour, T., . . . Murage, M. (2023). Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA. Clinical Drug Investigation, 43(3), 185. https://doi.org/10.1007/s40261-022-01240-9

Chicago Style (17th ed.) Citation

Blauvelt, Andrew, et al. "Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA." Clinical Drug Investigation 43, no. 3 (2023): 185. https://doi.org/10.1007/s40261-022-01240-9.

MLA (9th ed.) Citation

Blauvelt, Andrew, et al. "Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA." Clinical Drug Investigation, vol. 43, no. 3, 2023, p. 185, https://doi.org/10.1007/s40261-022-01240-9.